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Background: Many studies of the eukaryotic transcription mechanism and its regulation rely on in vitro assays.
Conventional RNA polymerase II transcription assays are based on radioactive labelling of the newly synthesized
RNA. Due to the inefficient in vitro transcription, the detection of the RNA involving purification and gel
electrophoresis is laborious and not always quantitative.
Results: Herein, we describe a new, non-radioactive, robust and reproducible eukaryotic in vitro transcription assay
that has been established in our laboratory. Upon transcription, the newly synthesized RNA is directly detected and
quantified using the QuantiGene assay. Alternatively, the RNA can be purified and a primer extension followed by
PCR detection or qPCR quantification can be performed. When applied to assess the activity of RNA polymerase II
inhibitors, this new method allowed an accurate estimation of their relative potency.
Conclusions: Our novel assay provides a non-radioactive alternative to a standard in vitro transcription assay that
allows for sensitive detection and precise quantification of the newly transcribed, unlabelled RNA and is particularly
useful for quantification of strong transcriptional inhibitors like α-amanitin. Moreover, the method can be easily
adapted to quantify the reaction yield and the transcription efficiency of other eukaryotic in vitro systems, thus
providing a complementary tool for the field of transcriptional research.Background
A tight regulation of gene expression is crucial for the
development of an organism and the maintenance of
cellular homeostasis, while aberrant gene expression
leads to disease-related altered phenotypes. The control
of transcription plays herein a key role, and research is
still ongoing to decipher its mechanisms. Many of these
studies rely on in vitro RNA polymerase II transcription
assays [1-3].
Effective transcription is especially critical for trans-
formed cells [4]. Since inhibition of transcription leads
to apoptosis regardless of the p53 status of the cells,
interfering with transcription is a promising therapeutic
strategy for developing new anticancer agents [5,6]. Several
common chemotherapeutic agents indirectly inhibit trans-
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reproduction in any medium, provided the orinhibition (camptotecin, doxorubicin) or by inhibiting
RNA polymerase II activation via cyclin-dependent kinase
inhibition (flavopyridol). Compounds that directly inhibit
the RNA polymerase II as the mushroom-derived amani-
tins (Figure 1A) are well-known toxins [7,8]. However, in
combination with antibodies targeting specific cancer anti-
gens they turn into potent and specific antineoplastic
agents [9,10]. For evaluation of the efficacy of new tran-
scription inhibitors derived from medicinal chemistry ap-
proaches, the quantification of inhibitory activity is
necessary. The activity of different compounds can be best
compared using a standardized in vitro polymerase II
transcription run-off assay [11,12].
For a typical polymerase II run-off reaction, a well-
defined nuclear extract providing the RNA polymerase II
and a basal set of transcription factors are used together
with a linear DNA template containing the desired pro-
moter. The newly synthesized RNA is radioactively labeled
by adding a 32P-CTP to the reaction mixture. After the
transcription reaction, the RNA has to be detected and/ord. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 1 Chemical structure of α-amanitin and amanitin-analogs tested in this paper. A. α-amanitin. B. O-methyl-γ-amanitin. C. HDP30.0378
[R = (CH2)6-NH2], HDP30.0516 [R = (CH2)8-NH2] and HDP30.0592 [R = (CH2)4-NH2]. D. HDP30.0346. E. HDP30.0445 [R = CH(CH3)–CH2-CH3] and
HDP30.0528 [R = CH2-OH]. F. HDP30.0470 [R
1 = CH(CH3)–CH2-CH3, R
2 = H] , HDP30.0797 [R1 = phenyl, R2 = H], HDP30.0841 [R1 = 4-flour-phenyl,
R2 = H], HDP30.0890 [R1 = 4-hydroxy-phenyl, R2 = H] and HDP30.0931 [R1 = CH2-OH, R
2 = CH2-OH].
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phenol-chloroform extraction and ethanol precipitation.
An RNA gel electrophoresis is performed and the labeled
RNA detected by autoradiography [1,2]. Alternatively,
when unlabeled, the purified RNA can be detected by pri-
mer extension using a fluorescently labeled primer [13].
After reverse transcription, the resulting cDNA is purified
and a gel electrophoresis performed.
However, these methods are difficult to use for an unex-
perienced laboratory. Since the synthesized amounts are
minute, reproducible and quantitative RNA recovery dur-
ing purification is challenging and strongly depends on
the experience of the laboratory staff. Quantification of
the newly synthesized RNA requires a phosphor-imaging
device. Moreover, because of the laborious and time-
consuming procedure, studies involving high numbers of
probes are difficult.
To overcome these limitations, our laboratory has de-
veloped a non-radioactive in vitro transcription assay
that relies on a commercially available eukaryotic tran-
scription kit and quantitative PCR RNA detection.
Moreover, the method was further optimized by using a
novel hybridization method for RNA detection and
quantification. With this optimized detection the purifica-
tion step can be avoided so that the method can be used
for the concomitant analysis of a considerable number of
samples including replicates. We applied both new
methods to quantify the activity of the strong RNA poly-
merase II direct inhibitor α-amanitin vs. natural, syntheticand semisynthetic amanitin-derivatives (Figure 1). More-
over, we employed the methods for quantification of tran-
scriptional activity from a promoter lacking the TATA
box, as well as of the inhibitory activity of flavopiridol,
which affects transcription by binding to the P-TEFb
kinase.
Results
Primer extension followed by PCR detection
For the first transcription followed by PCR detection ex-
periments, the well-characterized plasmid pEGFP-N1
(Clontech, acc. no. U55762) was directly used as a tem-
plate. The reactions were set up using the HeLa Scribe
kit without adding radioactive nucleotides. To assess
transcription inhibition, α-amanitin or other compounds
were added in various concentrations to the reaction
mix. A transcription reaction mixture that did not in-
clude NTPs served as a negative control, since it con-
tained the same amount of template DNA and would
thus monitor DNA interference. After transcription, the
newly synthesized RNA was purified and DNase digested.
For RNA detection, a primer pair was designed and used
in a reverse transcription plus PCR approach to amplify a
295 bp long DNA stretch within the first 400 bp of the
EGFP transcript (Table 1). Figure 2A shows the agarose
gel of the amplified products. A DNA fragment of ex-
pected length was synthesized using the RNA from the
positive transcription reaction, while RNA from the reac-
tion without NTPs showed no product, proving that the
Table 1 Primer and probe sequences for amplification and detection
Template Primer/oligo Sequence 5′-3′ Modification Amplicon/probe
Plasmid pEGFP-N1 CMV-EGFP-frw GGGGCGGAGCCTATGGAAAA - PCR product: (5′ biotinyl-)CMV-EGFP,
1136 bp
Btn-CMV-EGFP-frw GGGGCGGAGCCTATGGAAAA 5′ biotin
CMV-EGFP-rev TGTCGCCCTCGAACTTCACCTC -
CMV-EGFP EGFPfrw1 TGAGCAAGGGCGAGGAGCTGTT - PCR/qPCR product, 295 bp
EGFPrev1 AAGATGGTGCGCTCCTGGACGT -
EGFPfrw2 GTGACCACCCTGACCTAC - qPCR product, 83 bp
EGFPrev2 ATGGCGGACTTGAAGAAG -
EGFP-LNA1 CAGtGCtTCaGCcGCTA* 5′ FAM, 3′ BHQ1,
LNA-oligo*
qPCR dual labeled probe
HeLaScribe ‘Positive
Control DNA’**
HELA NUCLEAR FW CTCATGTTTGACAGCTTATCGATCCGGGC - PCR product: (5′ biotinyl-)HS-DNA,
1182 bp
Btn-HELA NUCLEAR FW CTCATGTTTGACAGCTTATCGATCCGGGC 5′ biotin
HELA NUCLEAR RV ACAGGACGGGTGTGGTCGCCATGAT -
HS-DNA HNqPCRfrw1 GCCGGGCCTCTTGCGGGATAT - qPCR product, 132 bp
HNqPCRrev1 CGGCCAAAGCGGTCGGACAGT -
HNqPCRfrw6 GTCCATTCCGACAGCATCGCCA - qPCR product, 144 bp
HNqPCRrev6 GGCTCCAAGTAGCGAAGCGAGC -
HN_SONDE1 TGGCGTGCTGCTAGCGCTAT 5′ FAM, 3′ BHQ qPCR dual labeled probe
*Locked Nucleic Acid (LNA) - bases are depicted as lower case.
**‘Positive Control DNA’ is provided with the Promega ‘HeLaScribe Nuclear Extract in vitro Transcription System’. Its DNA sequence is provided within the
Additional file 1 “HeLaScribe Positive Control DNA Sequence”.
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addition of α-amanitin to the transcription mix resulted in
a clearly diminished amount of PCR product.
The residual transcriptional activity that was observed
in the presence of 100 μM α-amanitin was attributed to
RNA polymerases I or III recognizing alternative bacter-
ial promoters on the plasmid. To minimize this interfer-
ence, CMV-EGFP, a 1136 bp linear DNA template
containing the CMV promoter and about 470 bp of theFigure 2 Detection of newly synthesized RNA by primer extension an
(A) or linearized CMV-EGFP template (B). The RNA was purified, reverse tran
demonstrating α-amanitin-sensitive RNA synthesis. 1- DNA ladder; 2- no α-am
NTPs); 5- positive PCR control; 6- DNase digested DNA control; 7- water PCR c
the α-amanitin concentration. 1- DNA ladder; 2- no α-amanitin; 3-5- 400, 100
amanitin analog 30.0346, respectively; 9- negative transcription control (withoEGFP transcript, was generated by PCR amplification.
Transcription reactions with this linear template fol-
lowed by the primer extension & PCR for detection
method showed gradually increasing inhibitory effects of
increasing α-amanitin concentrations (Figure 2B). In
contrast, a synthetic α-amanitin derivative (HDP30.0346,
Figure 1B) containing only the left ring of the α-
amanitin bicyclic octapeptidic structure showed in this
experiment no inhibitory activity.d PCR. In vitro transcription was performed on the pEGFP-N1 plasmid
scribed and detected by PCR. A. Gel analysis of the PCR products
anitin; 3- 100 μM α-amanitin; 4- negative transcription control (without
ontrol. B. The visualized PCR product amount inversely correlated with
and 20 μM α-amanitin, respectively; 6-8- 400, 100 and 20 μM synthetic
ut NTPs); 10- positive PCR control; 11-water PCR control.
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To quantitate the observed gradual inhibition by α-
amanitin, the established PCR was replaced by a stand-
ard qPCR with SYBR green quantification. Despite the
promising PCR results, in a first qPCR experiment no
differences were observed, although the same RNA sam-
ples and primers were used. The product melting curve
analysis showed that unspecific products interfered with
the quantification. SYBR dye-based quantification was
thus replaced by quantification via the dual-labeled
sequence-specific probe EGFP-LNA1 (Table 1). EGFP-
LNA1-based quantification revealed a clear difference
between the positive, negative and inhibited reactions
(Figure 3A). However, the efficiency of the qPCR reac-
tions dropped significantly upon using the probe, and no
α-amanitin-concentration dependency could be dis-
cerned even when using the linear CMV-EGFP fragment
as a template (Figure 3B).
On the other hand, when comparing RNA samples de-
rived from different in vitro transcription experiments, a
very good reproducibility of RNA detection and quantifi-
cation was observed (Figure 3C). RNA samples fromA
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Figure 3 Detection of newly synthesized RNA by primer extension an
(A, C) or linearized CMV-EGFP template (B, C, D). The RNA was purified, re
of the primer-extension products from A as detected by a sequence-specif
100 μM) of 22.3 was significantly lower than that of the probe generated w
amounts. B. qPCR amplification of RNA/cDNA after in vitro transcription from
showed no clear α-amanitin-concentration dependency. -αA – positive transc
transcription, C(T) values 27.9, 37.0, 28.1 and 24.5 for 100, 50, 20 and 2 μM, res
digested DNA control. C. Amplification curves of RNA products from three dif
at different occasions resulted in very similar C(T) values of 17.6, 18.0 and 16.1
controls. Note that the inhibitory effect of α-amanitin was dramatically increas
(Exp3, C(T) = 27.9), when compared to Exp1 and Exp2 (C(T) values 22.3 and 21
template. αA – transcription without α-amanitin; +αA - transcription in the pr
quantitative estimation of the relative inhibitory activity of α-amanitin and sev
γ-amanitin; Amanitin = α-amanitin. Two different charges of the analog HDP3different translation reactions performed at different oc-
casions showed very similar fluorescence levels and C(T)
values. Interestingly, the inhibitory effect of 100 μM α-
amanitin was clearly stronger in reactions performed
with the linear DNA template (Experiments 1 and 2),
when compared to the transcription reactions on the cir-
cular plasmid template (Experiment 3).
This qPCR setting was subsequently used to compare
the inhibitory activity of α-amanitin and several analogs
in a single experiment. The methylated amanitin variant
6′–O-methyl-γ-amanitin (Figure 1C) was used in a con-
centration range similar to α-amanitin (5-100 μM), while
the concentrations of synthetic ones were chosen 10-
fold higher (400-1000 μM). For quantification, a stand-
ard curve of the linear template CMV-EGFP was used.
The results of this experiment demonstrated that this
method allowed for a semi-quantitative comparison of
α-amanitin and analogs (Figure 3D). 6′–O-methyl-γ-am-
anitin, an about two-fold less potent RNA polymerase II
inhibitor than α-amanitin [14], showed an inhibitory ac-
tivity similar to that of α-amanitin in our setting. One of
the synthetic compounds, HDP30.0445 (Figure 1D), anB
D
























d qPCR. In vitro transcription was performed on the pEGFP-N1 plasmid
verse transcribed and detected by qPCR. A. qPCR amplification curves
ic LNA probe. The C(T) value of the α-amanitin-inhibited probe (+αA
ithout amanitin (−αA, c(T) = 17.6) indicating significantly lower RNA
the linear template CMV-EGFP in the presence of 5-100 μM α-amanitin
ription (without α-amanitin, C(T) = 16.1); +αA – α-amanitin-inhibited
pectively; −NTP/-αA – negative control transcription; DNase - DNase
ferent experiments (Exp1-Exp3). Positive transcription reactions performed
for Exp1, 2 and 3, respectively. No amplification occurred for the negative
ed when the linearized template CMV-EGFP was used for transcription
.7, respectively), were the supercoiled plasmid pEGP-N1 was used as a
esence of α-amanitin; −NTP/-αA – negative control transcription. D. Semi-
eral semisynthetic and synthetic analogs. 6–O-Met-γ-Ama = 6′-O-methyl-
0.0470 were tested.
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cine replacing the naturally occurring di-hydroxy-
isoleucine as amino acid 3 (aa3) of α-amanitin, was free
of inhibitory activity despite the high concentrations
tested. The synthetic α-amanitin analogs HDP30.0528
(Figure 1D), containing an open left ring and serine in-
stead of the di-hydroxy-isoleucine as aa3, as well as
HDP30.0470 (Figure 1E), an isoleucine-amanitin analog
with closed left ring showed at both tested concentra-
tions an inhibitory activity that was comparable with the
activity of α-amanitin at the 10–100 - fold lower concen-
trations. These results demonstrated that the assay estab-
lished so far allowed for a qualitative assessment of the
inhibitory activity. However, smaller differences in the po-
tency of various inhibitors could not be determined.
Attempts for qPCR optimization including the use of
an alternative primer pair, EGFP-frw2 and EGFP-rev2
amplifying a shorter PCR fragment (Table 1), did not lead
to any significant improvement. Since the EGFP template
was not suited for more effective primer design, the posi-
tive control DNA provided in the HeLaScribe kit was
chosen as an alternative. Primers were designed to amplify
the HS-DNA linear fragment containing the CMV
promoter and the transcribed sequence (Table 1 and
Additional file 1). Several different primers pairs and two
sequence specific probes were designed within the tran-
scribed sequence (Table 1). Upon optimization, the
primer-probe mix H1 gave the best qPCR results.
Template immobilization and optimized qPCR
quantification
To remove the DNA after transcription, the two bio-
tinylated linear DNA templates CMV-EGFP and HS-
DNA were synthesized and immobilized on magnetic
beads. qPCR analysis of the supernatant, however,
showed that the DNA interference was still considerable
(Table 2 and Additional file 2: Figure S1A). The RNA
purification step could thus not be avoided by using theTable 2 Template comparison
Template qPCR C(T) values qPCR C(T) values
No RNA purification RNA purification
Positive Negative Positive Negative
CMV-EGFP
Free 32.6 31.6 17.4 >40
Beads 37.3 >40 23.2 >40
HS-DNA
Free 27.7 22.3 30.3 37.0
Beads 28.1 29.6 20.7 >40
Two different linear DNA templates, CMV-EGFP or HS-DNA in solution (free) or
immobilized on magnetic beads (beads) were used. Only positive transcription
(+) and negative control reactions (−) were performed, and the product
detected using primer extension and qPCR. C(T) values for the positive reactions
should be lower than 25, values over 30 for the positive reactions reflect RNA
synthesis levels that are too low to allow reliable inhibition quantification.
Negative reactions should result in C(T) values higher than 35. C(T) values > 40
reflect no amplification, i.e. no detectable RNA synthesis.immobilized template. Since the bead-bound HS-DNA
was most efficiently transcribed, even when compared to
the free linear one (see Additional file 2: Figure S1B), it
was chosen as a template for all subsequent experiments.
A series of transcription and qPCR optimization ex-
periments resulted in an optimized method for the
in vitro RNA polymerase assay, which is detailed in the
Additional file 3. This method was applied to assess the
inhibitory activity of α-amanitin in several independent
experiments. The quantification of the synthesized RNA
showed a clear α-amanitin-concentration dependency
(Figure 4A & B) and a very good reproducibility over
several experiments (Figure 4B).
When applied to assess the inhibitory activity of sev-
eral α-amanitin analogs vs. α-amanitin, this optimized
method allowed for a quantitative estimation of the in-
hibitory potency using the inhibition concentration 50
(IC50) values (Figure 4C). Three of the tested synthetic
α-amanitin analogs HDP30.797 (Figure 1E, IC50 = 314 μM),
HDP30.841 (Figure 1E, IC50 = 2.1 mM) and HDP30.890
(Figure 1E, IC50 = 1.4 mM), sharing the α-amanitin struc-
ture but with the natural amino acid 3 (aa3) di-hydroxy-
isoleucine replaced by different synthetic phenyl-glycine
derivatives, showed 150-1000-fold weaker inhibitory
activity than α-amanitin (IC50 = 2.1 μM). The α-amanitin-
analog HDP30.0931 (Figure 1E), an aa3 α,α-dihydroxy-
methyl-glycine derivative, showed no inhibitory activity up
to concentrations as high as 10 mM (IC50 > 10 mM).
RNA polymerase assay with Quantigene quantification
The optimized qPCR detection method allowed for very
precise and specific RNA quantification after transcrip-
tion. However, due to the indispensable RNA purifica-
tion step, the assay remained very laborious. The
Affimetrics QuantiGene assay, described as a qPCR al-
ternative, which still allows detection of minute RNA
amounts but does not require RNA purification, was
considered and tested. For a first attempt, RNA was
transcribed by the optimized method in positive and
negative (no NTPs) in vitro transcription reactions. After
transcription, half of the reaction mixture was used for
RNA purification and the synthesized RNA amount was
quantified using the optimized qPCR method. The un-
purified positive reaction mixture and the purified RNA
derived from it were then serially diluted and assessed
by the QuantiGene method.
A clear RNA concentration dependency of the signal
was seen for both the purified RNA and the unpurified
reaction mixture dilutions (Figure 5A). Moreover, the
signal showed a clear linear relationship to the degree of
dilution over three orders of magnitude. The purified
RNA from the negative control showed as expected only
a background-level signal, but a significant signal, prob-
ably derived from DNA interference, was observed in
AB
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Figure 4 Quantitative analysis of RNA synthesis by optimized
qPCR. In vitro transcription was performed using the linear, bead
immobilized DNA template Bead-HS-DNA. Each reaction was
performed in duplicate. The RNA was purified, DNase digested and
analyzed by reverse transcription followed by qPCR amplification.
A. The amplification curves of RNA products derived from uninhibited
and α-amanitin-containing reactions showed gradually decreasing C(T)
values with increasing α-amanitin concentrations. For each type of
reaction, the average fluorescence values were plotted. -αA –
transcription reactions without α-amanitin; +αA - transcription
reactions in the presence of α-amanitin; −NTP/-αA – negative control
transcription reactions. B. Graphic representation of the calculated
percent RNA synthesis in the presence of amanitin derived from the
qPCR curves presented in A and from two additional similar experiments.
Due to the high amanitin concentrations used, the residual percent RNA
synthesis was lower than 10% and is depicted in a logarithmic scale.
C. The optimized method was used to compare the inhibitory activity
of amanitin to that of four synthetic analogs. B & C. The newly
synthesized RNA amount was calculated using a DNA standard curve.
By relating to the RNA amount synthesized in the uninhibited reactions
a residual percent RNA synthesis was calculated. Bars show standard
deviation.
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was assessed without prior RNA purification. However,
this signal (236,494 RLU), derived from an 1:2 diluted
reaction mixture was <20% when compared to the signal
of the 1:10 dilution of the reaction mix (1,991,564).
A second experiment was set up to compare the
QuantiGene and qPCR detection of in vitro transcribed
RNA from a set of reactions containing serial α-
amanitin dilutions. For qPCR quantification, half of the
reaction mix was subject to RNA purification. Three dif-
ferent series were used to the QuantiGene detection: an
aliquot of the purified RNA, a dilution prepared directly
from the reaction mix and the same reaction mix dilu-
tion that was digested by DNase prior QuantiGene as-
sessment. As expected, almost identical inhibition curves
were obtained when the purified RNA was assessed by
the QuantiGene or qPCR methods. Most importantly,
the inhibition curves derived from the reaction mix sam-
ples also showed a clear concentration dependency and
did not differ significantly from the curves achieved
using the purified RNA, regardless of the DNase digestion
step (Figure 5B). The QuantiGene RNA quantification
method therefore proved to be a worthy alternative for
the reverse transcription plus qPCR, combining its sensi-
tivity with the huge benefit of avoiding RNA purification.
This method was thus applied to compare the inhibi-
tory activity of α-amanitin and α-amanitin-derivatives in
a series of in vitro transcription reactions (Figure 5C). In
this experiment, three semisynthetic amanitin-linker
derivatives were assessed, all of them being methylated
on the hydroxyl-group of amino acid 4, 6-hydroxy-
tryptophan, and containing the linker bound to the N1
of the same amino acid. These compounds only differed
in the linker length, which varied between four, six and
eight carbon atoms in HDP30.0592, HDP30.0378 and
HDP30.0516 (Figure 1F), respectively. The IC50 values of
the three compounds, HDP30.0592 (IC50 = 321 μM),
HDP30.0378 (IC50 = 180 μM) and HDP30.0516 (IC50 =
629 μM), were 30-100-fold lower than of α-amanitin
(IC50 = 5.7 μM), demonstrating that all these compounds
could still bind to the RNA polymerase II despite methy-
lation and substitution by linker, and that an optimum
of activity could be achieved when using a linker with a
length of 6C atoms.
Effect of TATA-binding protein (TBP) on the transcription
efficiency
To assess for transcription efficiency in the absence of
TBP activity, a template lacking the TATA box was used,
in which the TATATA sequence had been substituted by
the TAGCTA sequence (Additional file 4). Positive,
negative and 200 nM α-amanitin-containing transcrip-
tion reactions were set up as duplicates using either the
standard bead-immobilized HS-DNA template or the
AB
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Figure 5 Quantitative analysis of RNA synthesis by QuantiGene method. A & B: In vitro transcription reactions were performed using the
linear, bead immobilized DNA template Bead-HS-DNA. Half of each reaction mixture was subsequently used for RNA cleanup and the RNA
amount was analyzed by the optimized qPCR method. A. Dilutions were either prepared directly from the reaction mixture or from the purified
RNA. Each dilution was assessed as a 4-fold replicate by the QG method. The chemoluminescence signals were plotted against the expected RNA
copy number, showing a clear linear relationship. Error bars show standard deviation. B. The optimized qPCR method was used to quantitate RNA
inhibition by α-amanitin as described in Figure 4. In parallel, purified RNA, diluted reaction mixtures or DNase-digested reaction mixture dilutions were
analyzed by the QG-method. Percent RNA synthesis was calculated by relating the luminescence signals of the respective α-amanitin-reaction to the
signal of the uninhibited reaction. The QG method provided clear α-amanitin-concentration dependency curves using unpurified RNAs directly from
the reaction mixture. C. The QG-method was applied to compare the inhibitory activity of α-amanitin to that of three semisynthetic derivatives. Bars
show the standard deviation of the duplicate samples.
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transcription and sedimentation of the beads, an aliquot
of each reaction mix was analyzed by the QuantiGene
assay as described in the Additional file 3. Quantificationof the newly synthesized RNA products revealed that an
amanitin-sensitive transcription occurred on both tem-
plates (Table 3). 200 nM α-amanitin inhibited the tran-
scription efficacy by 88 ± 1% for both templates. When
Table 3 Effect of TATA-binding protein on the transcription efficiency
Template Reaction Signal
(RLU average)
% RNA synthesis* % RNA synthesis
TATA mutant vs. standard**
HS-DNA_std
Positive 1306740 100% ± 3% 100% ± 3%
Negative 9768
α-amanitin 200 nM 161585 12% ± 1%
HS-DNA_mut
Positive 985650 100% ± 10% 75% ± 7%
Negative 11795
α-amanitin 200 nM 130255 12% ± 1%
Transcription reactions were performed using the standard DNA template (HS-DNA_std) or a TATA-box mutated template (HS-DNA_mut). Transcription efficacy
was determined by QuantiGene quantification.
*Compared to respective average positive control, less the respective negative controls.
**Compared to average positive control on standard template, less the respective negative controls.
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cacy from the template with mutated TATA box was 20-
30% lower.
qPCR and QuantiGene quantification of the inhibitory
effects of flavopiridol
Both the optimized qPCR detection method as well as
the QuantiGene method were applied to assess the fla-
vopiridol effect on the transcription efficacy. Transcrip-
tion reactions were performed and analyzed as described
in the detailed protocol in the Additional file 3. Flavopir-
idol was added in concentrations ranging from 200 nM
to 625 mM, parallel control reactions contained 64 pM
to 200 nM α-amanitin. The first set of reactions was per-
formed using the standard bead-immobilized HS-DNA
template and the transcription reactions were incubated
for 30 min at 30°C. A second set of reactions was per-
formed using the longer template HS-DNA_long sharing
the same promoter but rendering a 98 bp longer tran-
script (456 vs. 358 bp) i.e. a 98 bp longer primer exten-
sion and qPCR detection fragment (Additional file 4).
This set of reactions was incubated for transcription for
a shorter period of 10 min (vs. 30 min for standard con-
ditions) at 30°C.
In contrast to α-amanitin which showed similar inhib-
ition effects regardless of the method used for quantifi-
cation, the measured inhibitory effects of flavopiridol on
the RNA synthesis depended on the quantification
method. Generally, the QuantiGene method resulted in
lower inhibition data (Figure 6A & C), while figures
generated by the primer extension & qPCR method
indicated higher inhibitory effects (Figure 6B & D).
Moreover, considering the figures from the qPCR quan-
tification method, a higher degree on inhibition was
measured for flavopiridol in the second set of reactions
generating the longer transcripts within a shorter incu-
bation period (IC50 = 940 nM, Figure 6B), when com-
pared to the first set (IC50 > 125 μM Figure 6D). In
contrast, the inhibitory effect of amanitin was ca. 10×
lower for the reactions with short incubation periods.Discussion
Eukaryotic transcription is a highly complex and tightly
regulated process and therefore extremely difficult to re-
constitute in vitro. It is commonly divided into the six
steps preinitiation, initiation, promoter escape/clearance,
elongation, and termination, all being the subject of tight
regulation. Except for the termination, an in vitro run-
off transcription system must emulate a proper environ-
ment for all these processes [15]. Transcription initiation
depends on the correct assembly of an active pre-
initiation complex at the site of the promoter. In the
past years, many different RNA polymerase II promoters
with different DNA sequences were described, requiring
multiple types of pre-initiation complexes to be formed
[16]. After initiation, RNA polymerase II starts RNA
synthesis by successively adding nucleotides to a growing
RNA chain. This “promoter clearance” [17,18] marks the
transition from initiation to elongation which is a highly
dynamic and tightly regulated stage of the eukaryotic
transcription, too [19,20]. Minimal requirements for
RNA polymerase II and cofactors for activity at specific
promoters are now known and highly purified transcrip-
tion systems have been described [21]. One commer-
cially available transcription system is the HeLaScribe
Nuclear Extract that has been used for the studies de-
scribed in this paper.
However, it is not trivial to perform an in vitro tran-
scription assays even when using a kit. In our hands, its
main limitation proved to be its ineffective initiation and
low rate of transcription that had been also described by
others [15]. The RNA amounts synthesized in one reac-
tion varied around 1×108 copies; the detection of such
small amounts in the presence of a 1000-fold excess
DNA template turned out to be very challenging. More-
over, for comparing various RNA polymerase II inhibi-
tors, a precise quantification of the synthesized RNA
was required. Gel electrophoresis and autography, as
normally used for RNA detection in the field of tran-
scription research, were not considered to fit for our
purpose.
A B
Transcript 358bp, 30min incubation, QG method Transcript 358bp, 30min incubation, qPCR method
C D
Transcript 456bp, 10min incubation, QG method Transcript 456bp, 10min incubation, qPCR method
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Figure 6 Comparison of the QuantiGene and qPCR methods as used for assessing the inhibitory effect of flavopiridol. A & B. Transcription
reactions in the presence of α-amanitin or flavopiridol were set up using the standard DNA template HS-DNA and performed following the
standardized protocol as described in the Additional file 3. C & D. A 98 pb longer DNA template, HS-DNA_long, was used to set up transcription
reactions in the presence of α-amanitin or flavopiridol. Reaction conditions were similar to the experiment in A & B except for a shorter incubation
period of 10 min instead of 30 min in the standard setting. To quantitate the RNA synthesis yield, the optimized, standardized QG- (A & C) or qPCR-
method (B & D) was applied. Residual percent RNA synthesis was calculated by relating to the RNA amount in the positive control reactions. Bars show
the standard deviation of the duplicate samples.
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since it had worked in our hands as an RNA polymerase
II template in cells upon transfection. For detection, the
primer extension method was chosen and complemen-
ted by a PCR step for signal amplification. The main
challenge of this system was to ensure that DNA con-
taminations would not interfere with the RNA quantifi-
cation. Two negative controls were designed to control
the DNA removal: the ‘negative control transcription’ re-
actions that contained the complete reaction mix includ-
ing the DNA but no NTPs, as well as a ‘DNase control’,
a DNA sample that was directly digested and then sub-
ject to reverse transcription and PCR as the purified
RNA samples.
The results of these experiments were highly encour-
aging, since the PCR method clearly detected newly
synthesized RNA and α-amanitin showed a concentration-
dependend effect on the detected RNA amount. This
concentration-dependency, however, could not be trans-
lated into numbers by switching to a qPCR detection sys-
tem, though the assay itself proved to be strikingly robust
and reproducible. Since there was no room for PCR
optimization within the EGFP translated sequence, an-
other DNA template had to be selected and the positive
control DNA from the HeLaScribe kit, the HS-DNA, was
chosen. For this template, a very efficient, sequence-specific probe dependent qPCR detection method was
established prior to proceeding with the further optimiza-
tion of the transcription assay.
In parallel, magnetic bead immobilization of the linear
DNA fragments was considered to avoid the very labori-
ous RNA purification step by fishing out the DNA from
the mixture. However, DNA contamination of the bead
supernatant exceeded the RNA amount and hindered its
direct quantification. On the other hand, transcription
from the immobilized HS-DNA template was very effi-
cient, so that the immobilization step was kept for the
optimized protocol. Interestingly, transcription from the
immobilized CMV-DNA was very poor. This probably is
due to the fact that the DNA stretch 5′ of the promoter
is much shorter in the CMV-EGFP DNA than in the
HS-DNA. Immobilization of the CMV-DNA template
probably results in a steric hindrance of the transcription
initiation step.
Finally, all steps of the transcription assay were opti-
mized for maximal efficiency and minimal complexity.
The transcription reaction volume was reduced back to
25 μl and reactions were performed as duplicates. For
the RNA purification, the RNeasy Micro kit was replaced
with the more convenient RNeasy Mini kit, which is also
available as a 96-well format. Freeze-drying the RNAs
overnight in a speedvac compensated the higher elution
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the DNase digestion buffer. The volume of the digestion
mixture that could be used for reverse transcription was
maximized and the reactions were set up in qPCR ves-
sels, so that the qPCR master mix aliquots could be
subsequently directly added. The qPCR parameters
temperature, concentration of primers, probe and Mg2+
were optimized for highest reaction efficiency.
This optimized method was ready to be applied to
quantitatively assess the inhibition profile of RNA poly-
merase II inhibitors. However, its requirement for RNA
purification limited the number of samples that could be
processed simultaneously. We therefore continued
searching for detection methods that would allow skip-
ping the purification step and identified the QuantiGene
assay as an alternative. The use of hybridization for the
RNA capture step renders this method very specific,
while multiple subsequent hybridization steps and an
enzymatic reaction achieve a high degree of amplifica-
tion and allow detection of very low amounts. We thus
tested this method for the quantitation of RNA directly
in the transcription mixture. Although some DNA inter-
ference in the negative controls leading to slightly posi-
tive detection results could not be avoided, the dynamic
range and linearity of the assay were compelling. A dir-
ect comparison of the results of the optimized qPCR
with the QuantiGene method finally demonstrated that
the latter provided similar results without a need for
RNA purification or DNase digestion, thus considerably
simplifying and speeding up the assay. Using the Quanti-
Gene assay, eukaryotic transcription assays can be per-
formed in a 96-well format and eventually fully
automatized, so that a high number of inhibitors can be
concomitantly analyzed.
Beside its simplicity, the main advantage of this new
method is the precise quantification of the transcription
reaction yield. For example, α-amanitin-derivatives
modified by the same linker chemistry that differed only
in the linker length showed distinct inhibition profiles
with the longest linker showing slightly less potency
than the shorter ones. This finding could be reproduced
in cells in cytotoxicity experiments, after the respective
amanitin-linker derivatives had been coupled to an IgG
targeting an antigen on the cells (data not shown).
In another set of experiments, the activity of flavopiri-
dol was assessed, an alternative inhibitor of transcription
elongation. Flavopiridol acts on transcription by stoi-
chiometric binding to P-TEFb, a protein kinase com-
posed of the cyclin-dependent kinase 9 (cdk9) and a
cyclin subunit, which regulates transcription elongation
by phosphorylating the C-terminal domain (CTD) of the
large subunit of the RNA polymerase II [22,23]. As ex-
pected, the measured inhibitory effect of flavopiridol on
the standard template was significantly lower comparedto α-amanitin. α-Amanitin directly binds with very high
affinity to the polymerase core subunit and blocks its
translocation to the next nucleotide [24], its IC50 inhib-
ition values thus depend on the concentration of RNA
polymerase core subunit. On the other side, by binding
to P-TEFb, flavopiridol inhibits the phosphorylation of
the RNA polymerase core subunit. Slower transcription
elongation at 20–50 nucleotides per min, however, oc-
curs even in the absence of CTD phosphorylation and
the resulting transcripts are therefore shorter [25]. The
quantification results reflected these features of flavopiri-
dol inhibition. A higher residual RNA synthesis rate was
measured by the QG method than by qPCR, due to the
synthesis of short RNA molecules that are missing the
reverse priming site used for primer extension and
qPCR. As expected, when a longer template was used
and the incubation time shortened, a significantly higher
inhibition degree was assessed for flavopiridol using the
qPCR method. However, more thorough investigations
would be required to explain the varied results from the
flavopiridol experiments.
But apart from a high-throughput assessment of tran-
scription inhibitors, the new methods can be employed
for a large variety of transcription-related applications,
since the transcript sequence can be combined with any
desirable promoter. As an example, a DNA template
containing a mutated TATA box was used for in vitro
transcription reactions in comparison to the wild-type
template. Using the QuantiGene quantification method
a transcription yield of ca. 75% of the wilde-type was ob-
served for the TATA mutant template. An intact TATA
box determines the transcription start position by provid-
ing the binding site for TBP but is not strictly required for
human transcription to occur. The mutation can cause a
shift of the start of transcription site to one or multiple
weaker ones, as well as influence the transcription efficacy
[26]. Our results suggest that the HeLa Scribe nuclear ex-
tract used contained several transcription initiation factors
that compensate for the absence of TBP binding and acti-
vate alternative pre-initiation pathways.
Moreover, provided that the composition of the tran-
scripts has been previously analyzed to ensure an accurate
interpretation of the results, the QuantiGene detection
can be easily adapted for the detection and quantification
of any specific transcript. The transcription reaction com-
position can be changed so that the effect of specific fac-
tors can be independently and quantitatively assessed. By
using immobilized DNA templates, pre-initiation com-
plexes can be assembled, isolated and their translational
activity further investigated. The immobilized linear DNA
can be processed to reconstitute a more physiological nu-
cleosomal template for in vitro transcription experiments,
since the ultrasensitive RNA detection compensates for
the low initiation efficacy of such in vitro transcription
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scripts would be required before determining potential
HTS set-up.
Conclusions
In conclusion, on the basis of a commercially available
kit we have established a relatively simple, robust and re-
producible non-radioactive method for RNA quantifica-
tion after eukaryotic in vitro transcription. We showed
that a simple qualitative PCR detection of the RNA tran-
script can be used after a run-off assay to avoid radio-
active labeling. Moreover, the optimized qPCR detection
method allows for unprecedented precise quantification
of the transcription efficacy. When using the Quanti-
Gene detection, the laborious RNA purification can be
avoided and a large number of samples processed
simultaneously.
Methods
Linear template amplification and immobilization;
oligonucleotide design
The pEGFP-N1 plasmid (Clontech, sequence accession
no. U55762) was used as a template for the amplification
of the 1136 bp linear DNA fragment CMV-EGFP using
the CMV-EGFP-frw and CMV-EGFP-rev primers. The
positive control DNA (for sequence see Additional file 1)
from the HeLaScribe Nuclear Extract in vitro Transcrip-
tion System (Promega) was used as a template for the
PCR-amplification of the 1182 bp linear DNA fragment
HS-DNA using the HELA NUCLEAR FW and HELA
NUCLEAR RV primers (for the sequences of all used
primers see Table 1). The same primers were used to amp-
lify the alternative linear fragments HS-DNA_mut and
HS-DNA_long containing either an intact promoter but a
mutated TATA box and the same transcripted region, or a
98 bp longer transcripted region with intact promoter and
TATA box (see Additional file 4). Amplified linear DNA
fragments were purified using the Qiagen QIAquick PCR
Purification Kit. This method does not remove the tem-
plate DNA from the mixture, which results in some plas-
mid contamination of the linear template. However, gel-
purified DNA did not work for in vitro transcription,
probably because of the dye interfering with the transcrip-
tion machinery. For immobilization of the linear templates
onto Dynabeads M280 (Life Technologies), the respective
5′-biotinilated forward primers were used. Bead immo-
bilization was performed as recommended by the manu-
facturer at 0.5 μg DNA per 100 μg beads and stored at
4°C in the binding buffer. The binding efficacy of about
80% resulted in a DNA concentration of 0.4 ng/100 g
beads. Prior to transcription reaction setup, the required
amount of loaded beads was transferred to a new tube
and washed there times with in vitro transcription
buffer.Two primer pairs were designed for PCR and qPCR
detection on the CMV-EGFP – derived RNA/cDNA, six
for the detection of the HS-DNA transcription product,
of which only the two sets showing satisfactory results
are shown in Table 1. For reverse transcription, the re-
verse primer closest to the transcript’s 5′ end was used,
i.e. EGFPrev1 for CMV-EGFP and HNqPCRrev1 for HS-
DNA. For Quantigene detection, the customized oligo-
nucleotide mix designed by the manufacturer based on
the sequence of the transcribed region of the HS-DNA
template.
Natural, synthetic and semisynthetic α-amanitin
derivatives; other chemicals
Flavopiridol was obtained from Sigma-Aldrich. α-Amanitin
(Figure 1A) was obtained from AppliChem. The semi-
synthetic amanitin derivative 6′–O-methyl-γ-amanitin
(Figure 1C) was a gift of Prof. H. Faulstich [14].
The semisynthetic linker derivatives HDP30.0378,
HDP 30.0516 and HDP 30.0592 (Figure 1F), derived
from natural α-amanitin, were obtained by methylation
of the phenolic group of the 6-hydroxytryptophan moi-
ety and subsequent alkylation of the indol nitrogen (N1)
of 6-O-methyl-α-amanitin using protected bromoalkana-
mines with different carbon lengths. Methylation was re-
quired to block the more acidic OH group. The (N1)–H
deprotonation reaction was performed using LiOH or
potassium-t-butoxide.
HDP30.0346 (Figure 1B) was synthesized by solid
phase peptide synthesis according to standard peptide
synthesis protocols. Thus Rink amide resin was used
followed by Fmoc peptide coupling. Key step was the in-
tegration of a cysteine-tryptophan precursor as described
in literature [27]. The pentamer was subsequently de-
protected and cleaved off from resin. The ring was fi-
nally cyclized in solution by use of standard coupling re-
agents under high dilution.
The synthetic derivatives HDP30.0445, 30.0528, 30.0470,
30.0797, 30.0841, 30.0890 and 30.0931 (Figure 1D & E)
were synthesized using standard peptide synthesis proto-
cols. The procedure for the transformation of the re-
spective linear octapeptides into the amanitin bicyclic
structure was based on the “Savige Fontana” technique
[28]. The monocyclic synthesis precursors HDP30.0445
and HDP30.0528 (Figure 1D) contain an open left side.
In vitro transcription assay followed by primer extension
and PCR/qPCR detection
Transcription reactions were set up as using the Promega
HeLaScribe Nuclear Extract in vitro Transcription System
were set up as described by the manufacturer with some
modifications. The reaction volume was doubled to 50 μl.
A master mix was prepared from a volume transcription
buffer (20 mM HEPES, pH 7.9, 100 mM KCl, 0.2 mM
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μl minus the nuclear extract volume, MgCl2 to a final con-
centration of 3 mM, 40 Units RNase inhibitor, DNA tem-
plate (1 μg pEGFP-N1 plasmid or 150 ng linear DNA
fragment CMV-EGFP, respectively) and the nuclear ex-
tract following the manufacturer’s recipe. Aliquots of the
master mix were transferred into reaction tubes contain-
ing different α-amanitin concentrations or water and
incubated for 20 min at room temperature. Standard tran-
scription reactions containing no α-amanitin were referred
as ‘positive’, reactions containing α-amanitin or other in-
hibitors as ’inhibited’. A standard reaction containing no
α-amanitin/inhibitors but also no NTPs was used as a
‘negative control transcription’. The reactions were started
by the addition of the NTP mix to a final concentration of
400 μM each, except for the negative control where water
was added. After incubating for 30 min at 30°C, the reac-
tions were stopped by diluting with 400 μl of the RLT
buffer from the Qiagen RNeasy Micro kit and stored at
−80°C until proceeding with RNeasy cleanup. This was
performed as recommended by the manufacturer, includ-
ing on-column DNase treatment but without the addition
of carrier RNA. The RNA was eluted using 15 μl water
and stored at −80°C.
The purified RNA was once more DNase-treated using
the Epicentre BaselineZero DNase kit as recommended
by the manufacturer, 8.8 μl of the RNA being digested in
a final volume of 10 μl. As a second negative control,
50 ng of the linear DNA fragment CMV-EGFP were dir-
ectly DNase-digested and further processed as the RNA
samples (‘DNase control’). For reverse transcription with
the Qiagen Sensiscript RT kit, 2 μl of the digestion reac-
tion and 1 μM EGFPrev1 primer (Table 1) were used in a
final reaction volume of 20 μl. After reaction, 1 μl of the
reverse transcription mix was transferred to PCR tubes
containing 24 μl PCR mix aliquots. The standard PCR
amplification was performed using the Epicentre Failsafe
PCR system with the Mix A and the EGFPrev1 and
EGFPfrw1 (Table 1) primer mix. Positive PCR control
reactions contained 50 ng pEGFP-N1 plasmid; negative
PCR controls contained no DNA. After amplification, the
products were analyzed by gel electrophoresis onto 1.5%
agarose.
For quantitation using SYBR detection, the Qiagen
QuantiFast SYBR green qPCR kit was used. 1 μl of the
reverse transcription mix was amplified in 25 μl reaction
mix containing 500 nM of each EGFP-rev1 and EGFP-
frw1 primer. For quantitation using the sequence-
specific LNA probe EGFP-LNA1 at 250 nM, same
primer set as well as an alternative primer set (EGFPfrw2
and EGFPrew2, Table 1) at 500 nM each and Sigma
Jumpstart Taq ReadyMix for qPCR were used. 2 μl of
the reverse transcription reaction were diluted into
qPCR reactions with a final volume of 20 μl and qPCRperformed in a Bio-Rad DNAEngine lightcycler. A qPCR
standard curve was prepared from the CMV-EGFP DNA
fragment and used for RNA copy number calculations.
The amount of RNA in the inhibited probes was related
to the RNA amount detected for the positive transcrip-
tion reaction. A particular compound concentration thus
shows an inhibitory effect if its ration is < 1.
In vitro transcription assay with immobilized templates
followed by qPCR quantification
Duplicate transcription reactions using immobilized
template were set up in 25 μl the same way as the reac-
tions with linear templates, except that the transcription
buffer was replaced by the freshly prepared DNA-bead
suspension in transcription buffer. The template amount
was set to 150 ng immobilized DNA per 50 μl reaction.
The required buffer volume and thus the bead concen-
tration were calculated considering the activity of the
nuclear extract charge used, as described in the HeLa-
Scribe manual. The master mix containing the bead sus-
pension in transcription buffer, 3 mM MgCl2 and 40
Units RNase inhibitor was supplemented with the HeLa
nuclear extract, mixed by gentle vortexing and dispersed
in aliquots into the reaction tubes. Water or α-amanitin
in various concentrations was added to the tubes, mixed
gently and incubated for 20 min at room temperature.
Reactions were started by the addition of the NTPs, ex-
cept for the negative control transcription reaction,
where water was added. During the 30 min incubation
at 30°C the reaction tubes were twice gently vortexed to
resuspend the beads.
After reaction, the beads were spun down and 20 μl of
the supernatants were diluted into the RLT buffer of the
Qiagen RNeasy Mini kit and stored at −80°C until pro-
ceeding to the RNA cleanup. The RNA was eluted from
the RNeasy mini-columns with 2×30 μl water and subse-
quently dried using a speed-vac. DNase digestion and re-
verse transcription steps were performed as described
above with some modifications. The dried RNA was dir-
ectly taken up into 10 μl DNase digestion mix. For re-
verse transcription in a final volume of 10 μl using 3 μl
of the DNase-digested RNA, the EGFP-rev1 (Bead-
CMV-EGFP template) or HNrev1 (Bead-HS-DNA tem-
plate) primers were used. After reverse transcription, 15
μl qPCR master mix aliquots were added directly to the
reverse transcription mixtures and the amplification was
performed as described. For the Bead-CMV-EGFP - de-
rived RNA the primer-probe-mix EGFP1 (final concentra-
tions EGFP-frw1 500 nM, EGFP-rev1 500 nM, EGFP-
LNA1 250 nM) was used, for the Bead-HS-DNA - derived
RNA the primer-probe-mix H1 (final concentrations
HNfrw1 500 nM, HNrev1 2 μM, HN_SONDE1 250 nM).
A qPCR standard curve was prepared from the respective
template DNA and used to calculate the RNA copy
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bers in the inhibited reactions to the copy number in the
positive transcription reactions, a percent transcription
inhibition was calculated for each compound and concen-
tration and an inhibition curve plotted. A sigmoidal dose–
response curve fit was used to calculate the compound
concentrations that inhibited RNA synthesis by 50% (inhi-
biting concentration 50, IC50).
RNA polymerase assay with QuantiGene quantification
Positive and negative control transcription reactions
using the bead-immobilized Bead-HS-DNA template
were set up as duplicates as described above in a final
volume of 100 μl per reaction. After transcription, 50 μl
of the reaction mixture were used for RNA cleanup. The
copy number of synthesized RNA was quantitated using
the established primer extension and qPCR method.
From this number, the RNA copy number in the reac-
tion mixture was estimated. Using the rest of the reac-
tion mixture of the positive reactions, a dilution series
was prepared starting at 1:10 unto 1:10,000. 0.3 mM
EDTA was added to the first dilution to bind Mg2+ that
would interfere with the QuantiGene capture step. Alter-
natively, a dilution series was prepared from the purified
RNA, starting at 1:100 unto 1:100,000. Both dilution
series were assessed using the QuantiGene 2.0 System
(Affimetrix) following the instructions provided by the
manufacturer. The negative control transcription reac-
tion products were only assessed as a 1:2 dilution for the
unpurified negative reaction mix or 1: 10 dilution for the
DNase-digested RNA purified from the negative control
transcription reaction.
For the capture step, the working reagent was pre-
pared according to the recipe provided in the ‘Capturing
Target RNA from Fresh, Frozen, or FFPE Tissue Ho-
mogenates’ section of the QuantiGene Handbook. 60 μl
of working reagent were distributed into the Quanti-
Gene plate and 40 μl of reaction mix or RNA dilution
were added. The subsequent hybridization, signal ampli-
fication and detection steps were performed as described
in the manual. Finally, the chemoluminescence signals
were measured using a FLUOstar Optima chemolumin-
ometer (BMG LABtech) and were plotted against the es-
timated RNA copy number.
For further experiments, positive, inhibited and nega-
tive control transcription reactions were set up in 25 μl
as duplicates covering a complete range of α-amanitin
or compound concentrations. After transcription, 20 μl
of the bead supernatant was used for RNA cleanup
followed by the optimized primer extension and qPCR
quantification method. 3 μl of the reaction mix were di-
luted with 97 μl water. 4 μl of this dilution were once
more diluted with 45 μl 0.3 mM EDTA containing
RNase-inhibitor (2U/μl). Alternatively, 36 μl DNase Zeromaster mix containing buffer, RNase inhibitor and en-
zyme were added to 4 μl of the reaction mix dilution
and DNase digestion was performed for 15 min at 37°C.
The digestion was stopped by the addition of 5 μl stop
solution (EDTA) and 10 min heating at 65°C. A blank
DNase digestion with water was used for the Qiagen
background sample. For QuantiGene quantification, 40
μl of the purified RNA, the twice diluted reaction mix or
the digested diluted reaction mix were added to 60 μl
working reagent in the QuantiGene capture plate. Upon
chemoluminescence detection, the background signals
were subtracted from the signals of the positive or inhib-
ited or negative control transcription samples. For each
sample type, reaction mixture, digested reaction mixture
and purified RNA, the negative control sample signals
were averaged and subtracted from the signals of the re-
spective positive and inhibited samples. A percent inhib-
ition was calculated by relating the signals of the
inhibited reactions to the signal derived from the posi-
tive transcription reactions, which were set to 100%. A
sigmoidal dose–response curve fit of the inhibition
curves was used to calculate the IC50 values of the tested
compounds.Additional files
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